EMA filing acceptance and validation for spesolimab

Boehringer Ingelheim announces European Medicines Agency ’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news